| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Organ Transplantation | 20 | 2021 | 2616 | 3.00 | Why? |
| Cytomegalovirus | 7 | 2019 | 600 | 1.73 | Why? |
| Cytomegalovirus Infections | 9 | 2019 | 667 | 1.65 | Why? |
| Transplant Recipients | 15 | 2021 | 4982 | 1.65 | Why? |
| Opportunistic Infections | 4 | 2019 | 602 | 1.21 | Why? |
| Graft Rejection | 5 | 2018 | 1766 | 1.08 | Why? |
| Influenza Vaccines | 5 | 2020 | 2941 | 0.99 | Why? |
| Lung Transplantation | 6 | 2021 | 1554 | 0.95 | Why? |
| Tissue and Organ Procurement | 4 | 2021 | 1277 | 0.91 | Why? |
| Influenza, Human | 8 | 2020 | 10779 | 0.76 | Why? |
| Tissue Donors | 6 | 2021 | 1679 | 0.70 | Why? |
| Bronchiolitis Obliterans | 2 | 2010 | 86 | 0.69 | Why? |
| Quinazolines | 1 | 2018 | 126 | 0.65 | Why? |
| Dose-Response Relationship, Immunologic | 1 | 2018 | 593 | 0.64 | Why? |
| Influenza A Virus, H3N2 Subtype | 2 | 2020 | 572 | 0.61 | Why? |
| Lymphoproliferative Disorders | 1 | 2017 | 110 | 0.61 | Why? |
| Allografts | 2 | 2019 | 761 | 0.57 | Why? |
| Viremia | 3 | 2019 | 1020 | 0.53 | Why? |
| Herpesvirus 4, Human | 1 | 2017 | 387 | 0.52 | Why? |
| Pneumonia, Pneumocystis | 1 | 2018 | 322 | 0.52 | Why? |
| Influenza B virus | 1 | 2020 | 815 | 0.52 | Why? |
| Epstein-Barr Virus Infections | 1 | 2017 | 366 | 0.49 | Why? |
| Immunity, Cellular | 3 | 2021 | 3614 | 0.47 | Why? |
| Immunocompromised Host | 8 | 2020 | 5150 | 0.45 | Why? |
| Donor Selection | 4 | 2020 | 804 | 0.45 | Why? |
| Immunogenicity, Vaccine | 3 | 2021 | 4624 | 0.43 | Why? |
| Mycobacterium tuberculosis | 1 | 2019 | 1164 | 0.39 | Why? |
| Ganciclovir | 3 | 2018 | 97 | 0.38 | Why? |
| Postoperative Complications | 5 | 2020 | 5861 | 0.37 | Why? |
| Viral Load | 5 | 2021 | 15850 | 0.35 | Why? |
| Interferon-gamma | 1 | 2018 | 2711 | 0.35 | Why? |
| Lung Diseases | 1 | 2021 | 2361 | 0.34 | Why? |
| Liver Transplantation | 4 | 2020 | 2864 | 0.34 | Why? |
| Transplants | 2 | 2020 | 136 | 0.33 | Why? |
| Immunosuppressive Agents | 8 | 2020 | 6331 | 0.31 | Why? |
| Canada | 7 | 2021 | 6018 | 0.30 | Why? |
| Community-Acquired Infections | 2 | 2010 | 2328 | 0.29 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2020 | 2984 | 0.29 | Why? |
| Graft Survival | 2 | 2018 | 587 | 0.28 | Why? |
| Immunoassay | 3 | 2022 | 4485 | 0.27 | Why? |
| Pneumococcal Vaccines | 1 | 2008 | 571 | 0.24 | Why? |
| Tuberculosis | 1 | 2019 | 2895 | 0.24 | Why? |
| Asymptomatic Infections | 1 | 2021 | 7218 | 0.23 | Why? |
| T-Lymphocytes | 1 | 2019 | 6670 | 0.22 | Why? |
| Invasive Pulmonary Aspergillosis | 2 | 2019 | 634 | 0.22 | Why? |
| Host vs Graft Reaction | 1 | 2018 | 1 | 0.19 | Why? |
| Hematopoietic Stem Cell Transplantation | 3 | 2018 | 2426 | 0.19 | Why? |
| Humans | 48 | 2022 | 930598 | 0.18 | Why? |
| Vaccine Potency | 1 | 2020 | 339 | 0.18 | Why? |
| Neuraminidase | 1 | 2020 | 289 | 0.18 | Why? |
| Echinocandins | 1 | 2018 | 139 | 0.17 | Why? |
| Marijuana Use | 1 | 2019 | 89 | 0.17 | Why? |
| Histocompatibility | 1 | 2017 | 53 | 0.17 | Why? |
| Middle Aged | 22 | 2021 | 270681 | 0.17 | Why? |
| Prospective Studies | 9 | 2021 | 43301 | 0.17 | Why? |
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2017 | 49 | 0.17 | Why? |
| Infectious Disease Medicine | 1 | 2020 | 311 | 0.17 | Why? |
| JC Virus | 1 | 2017 | 39 | 0.17 | Why? |
| Respiratory Tract Infections | 2 | 2010 | 6817 | 0.16 | Why? |
| Mannans | 1 | 2018 | 218 | 0.16 | Why? |
| Acetates | 1 | 2018 | 123 | 0.16 | Why? |
| Leukoencephalopathy, Progressive Multifocal | 1 | 2017 | 55 | 0.16 | Why? |
| Interferon-gamma Release Tests | 1 | 2019 | 253 | 0.16 | Why? |
| Polyethylene Glycols | 1 | 2021 | 574 | 0.15 | Why? |
| Antibodies, Viral | 4 | 2021 | 51949 | 0.15 | Why? |
| Antigens | 1 | 2018 | 267 | 0.15 | Why? |
| Bronchoalveolar Lavage Fluid | 2 | 2018 | 2309 | 0.15 | Why? |
| Double-Blind Method | 3 | 2021 | 5988 | 0.15 | Why? |
| Interleukins | 1 | 2021 | 762 | 0.14 | Why? |
| Critical Illness | 2 | 2021 | 17281 | 0.14 | Why? |
| CD4 Lymphocyte Count | 1 | 2020 | 1517 | 0.14 | Why? |
| Female | 21 | 2021 | 380317 | 0.14 | Why? |
| Virus Shedding | 2 | 2021 | 5834 | 0.14 | Why? |
| Male | 23 | 2021 | 367725 | 0.14 | Why? |
| Drug Resistance, Viral | 2 | 2020 | 1083 | 0.14 | Why? |
| Risk Factors | 10 | 2019 | 71621 | 0.13 | Why? |
| Immunization Schedule | 2 | 2018 | 1305 | 0.13 | Why? |
| Adult | 17 | 2021 | 244371 | 0.13 | Why? |
| Immune System Diseases | 1 | 2018 | 410 | 0.13 | Why? |
| Vaccination | 4 | 2019 | 19050 | 0.12 | Why? |
| Aged | 15 | 2021 | 215776 | 0.12 | Why? |
| Candidemia | 1 | 2017 | 353 | 0.12 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2020 | 5837 | 0.12 | Why? |
| Antitubercular Agents | 1 | 2019 | 775 | 0.12 | Why? |
| Ontario | 1 | 2019 | 1966 | 0.12 | Why? |
| Ambulatory Care | 2 | 2021 | 4947 | 0.11 | Why? |
| Bronchoalveolar Lavage | 2 | 2019 | 603 | 0.11 | Why? |
| Antifungal Agents | 2 | 2019 | 1828 | 0.11 | Why? |
| T-Lymphocyte Subsets | 1 | 2019 | 1387 | 0.11 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.10 | Why? |
| Practice Guidelines as Topic | 5 | 2019 | 15421 | 0.10 | Why? |
| Immunization, Secondary | 1 | 2018 | 1649 | 0.10 | Why? |
| Travel-Related Illness | 1 | 2018 | 1357 | 0.10 | Why? |
| RNA Viruses | 1 | 2017 | 824 | 0.10 | Why? |
| DNA, Viral | 2 | 2018 | 2521 | 0.10 | Why? |
| Young Adult | 7 | 2021 | 93724 | 0.10 | Why? |
| Perioperative Care | 1 | 2020 | 1329 | 0.10 | Why? |
| Vaccination Coverage | 1 | 2018 | 1249 | 0.09 | Why? |
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2008 | 64 | 0.09 | Why? |
| Antiviral Agents | 8 | 2021 | 41703 | 0.09 | Why? |
| Seroconversion | 1 | 2018 | 2515 | 0.09 | Why? |
| Pennsylvania | 1 | 2010 | 558 | 0.09 | Why? |
| Incidence | 4 | 2021 | 25622 | 0.08 | Why? |
| Forced Expiratory Volume | 1 | 2010 | 632 | 0.08 | Why? |
| Global Health | 3 | 2020 | 13911 | 0.08 | Why? |
| Dyspnea | 1 | 2020 | 3847 | 0.08 | Why? |
| Cytokines | 2 | 2019 | 15010 | 0.08 | Why? |
| Bacteremia | 1 | 2017 | 1372 | 0.08 | Why? |
| Adolescent | 5 | 2021 | 86841 | 0.08 | Why? |
| Decision Making | 1 | 2020 | 3132 | 0.07 | Why? |
| Vulnerable Populations | 1 | 2020 | 3099 | 0.07 | Why? |
| Communicable Diseases, Emerging | 1 | 2020 | 2523 | 0.07 | Why? |
| Autoimmune Diseases | 1 | 2019 | 1996 | 0.07 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.07 | Why? |
| Drug Therapy, Combination | 1 | 2019 | 7268 | 0.07 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.07 | Why? |
| Follow-Up Studies | 3 | 2018 | 17020 | 0.07 | Why? |
| Brain | 2 | 2019 | 5133 | 0.07 | Why? |
| Treatment Outcome | 5 | 2021 | 51732 | 0.07 | Why? |
| MicroRNAs | 1 | 2017 | 1787 | 0.07 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2017 | 3388 | 0.06 | Why? |
| Communicable Diseases | 1 | 2018 | 2148 | 0.06 | Why? |
| Tertiary Care Centers | 1 | 2021 | 8248 | 0.06 | Why? |
| Pneumococcal Infections | 1 | 2008 | 562 | 0.06 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.06 | Why? |
| Antineoplastic Agents | 1 | 2018 | 3550 | 0.06 | Why? |
| Infant | 3 | 2020 | 30274 | 0.06 | Why? |
| Time Factors | 2 | 2019 | 31397 | 0.06 | Why? |
| Aged, 80 and over | 4 | 2021 | 88759 | 0.06 | Why? |
| Host-Pathogen Interactions | 2 | 2019 | 11041 | 0.06 | Why? |
| Biopsy | 1 | 2010 | 2811 | 0.05 | Why? |
| Antigens, Viral | 1 | 2018 | 6298 | 0.05 | Why? |
| Infection Control | 2 | 2020 | 23131 | 0.05 | Why? |
| Patient Acceptance of Health Care | 1 | 2019 | 5002 | 0.05 | Why? |
| Virus Diseases | 1 | 2017 | 3779 | 0.05 | Why? |
| Spain | 1 | 2018 | 15545 | 0.05 | Why? |
| Cell-Derived Microparticles | 1 | 2021 | 134 | 0.05 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2003 | 12361 | 0.05 | Why? |
| Retrospective Studies | 4 | 2019 | 105322 | 0.05 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.05 | Why? |
| Intention to Treat Analysis | 1 | 2021 | 673 | 0.05 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.05 | Why? |
| DNA Primers | 1 | 2003 | 1170 | 0.05 | Why? |
| Vaccines | 1 | 2018 | 3692 | 0.05 | Why? |
| Virus Replication | 2 | 2017 | 14331 | 0.05 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.05 | Why? |
| Activation, Metabolic | 1 | 2017 | 6 | 0.04 | Why? |
| Leukocytes, Mononuclear | 2 | 2019 | 2115 | 0.04 | Why? |
| Child, Preschool | 2 | 2020 | 36283 | 0.04 | Why? |
| Kidney Transplantation | 1 | 2018 | 5397 | 0.04 | Why? |
| Galactose | 1 | 2018 | 201 | 0.04 | Why? |
| Immediate-Early Proteins | 1 | 2017 | 44 | 0.04 | Why? |
| Serum | 1 | 2019 | 294 | 0.04 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.04 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.04 | Why? |
| Internship and Residency | 1 | 2018 | 4987 | 0.04 | Why? |
| Acute Disease | 1 | 2010 | 6029 | 0.04 | Why? |
| Prognosis | 2 | 2018 | 32490 | 0.04 | Why? |
| United States | 3 | 2018 | 46150 | 0.04 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.04 | Why? |
| Pneumonia | 1 | 2017 | 5652 | 0.04 | Why? |
| Prevalence | 1 | 2019 | 25773 | 0.04 | Why? |
| Half-Life | 1 | 2017 | 298 | 0.04 | Why? |
| Oseltamivir | 1 | 2020 | 583 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 8811 | 0.04 | Why? |
| Aspergillus | 1 | 2019 | 347 | 0.04 | Why? |
| Base Sequence | 1 | 2003 | 3581 | 0.04 | Why? |
| Child | 3 | 2020 | 70012 | 0.04 | Why? |
| Risk Assessment | 3 | 2019 | 25439 | 0.04 | Why? |
| Lung | 2 | 2021 | 31049 | 0.04 | Why? |
| Cross Infection | 1 | 2017 | 8675 | 0.03 | Why? |
| Disease Transmission, Infectious | 1 | 2017 | 9044 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.03 | Why? |
| Transplantation, Homologous | 1 | 2017 | 757 | 0.03 | Why? |
| Cell Membrane | 1 | 2019 | 743 | 0.03 | Why? |
| RNA, Viral | 2 | 2021 | 32276 | 0.03 | Why? |
| Carbapenems | 1 | 2017 | 343 | 0.03 | Why? |
| Phosphorylation | 1 | 2017 | 1060 | 0.03 | Why? |
| HeLa Cells | 1 | 2017 | 1303 | 0.03 | Why? |
| Population Surveillance | 1 | 2010 | 4967 | 0.03 | Why? |
| Drug Monitoring | 1 | 2021 | 1408 | 0.03 | Why? |
| Graft vs Host Disease | 1 | 2017 | 501 | 0.03 | Why? |
| Latin America | 1 | 2018 | 1721 | 0.03 | Why? |
| Kinetics | 1 | 2020 | 3238 | 0.03 | Why? |
| High-Throughput Screening Assays | 1 | 2021 | 1783 | 0.03 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.03 | Why? |
| Surveys and Questionnaires | 4 | 2019 | 43792 | 0.03 | Why? |
| Waiting Lists | 1 | 2019 | 1388 | 0.03 | Why? |
| Cluster Analysis | 1 | 2019 | 3001 | 0.03 | Why? |
| Reagent Kits, Diagnostic | 1 | 2021 | 2149 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Fellowships and Scholarships | 1 | 2018 | 931 | 0.02 | Why? |
| Neoplasms | 1 | 2018 | 17251 | 0.02 | Why? |
| Patient Education as Topic | 1 | 2019 | 1476 | 0.02 | Why? |
| Immune System | 1 | 2019 | 1479 | 0.02 | Why? |
| Personal Satisfaction | 1 | 2018 | 1243 | 0.02 | Why? |
| Clinical Protocols | 1 | 2020 | 2734 | 0.02 | Why? |
| Communicable Disease Control | 1 | 2017 | 29620 | 0.02 | Why? |
| Phenotype | 1 | 2019 | 4037 | 0.02 | Why? |
| Hepatitis C | 1 | 2019 | 1514 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2021 | 3129 | 0.02 | Why? |
| Software | 1 | 2019 | 2501 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2017 | 1414 | 0.02 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.02 | Why? |
| Bacteria | 1 | 2017 | 1897 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Transcriptome | 1 | 2019 | 3466 | 0.02 | Why? |
| Immunoglobulins, Intravenous | 1 | 2017 | 2705 | 0.02 | Why? |
| Liver | 1 | 2019 | 4007 | 0.02 | Why? |
| Patient Care Team | 1 | 2019 | 3556 | 0.02 | Why? |
| Curriculum | 1 | 2018 | 3083 | 0.02 | Why? |
| Mortality | 1 | 2021 | 7132 | 0.02 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.02 | Why? |
| Fever | 1 | 2020 | 7795 | 0.02 | Why? |
| Consensus | 1 | 2018 | 6345 | 0.02 | Why? |
| Contact Tracing | 1 | 2003 | 8448 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2017 | 3755 | 0.02 | Why? |
| Disease Management | 1 | 2021 | 6841 | 0.02 | Why? |
| RNA, Messenger | 1 | 2017 | 5131 | 0.01 | Why? |
| Mobile Applications | 1 | 2018 | 3032 | 0.01 | Why? |
| Disease Progression | 1 | 2021 | 13580 | 0.01 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.01 | Why? |
| Algorithms | 1 | 2019 | 7346 | 0.01 | Why? |
| Cohort Studies | 1 | 2005 | 36005 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 11367 | 0.01 | Why? |
| Cell Line | 1 | 2017 | 12040 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Magnetic Resonance Imaging | 1 | 2017 | 6551 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.01 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.01 | Why? |
| Models, Theoretical | 1 | 2017 | 6659 | 0.01 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.01 | Why? |
| Inflammation | 1 | 2019 | 13255 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| HIV Infections | 1 | 2019 | 11620 | 0.01 | Why? |